

Special Issue

Emerging Biomarkers for Immune Checkpoint Inhibitor Sensitivity and Resistance in Non-Small-Cell Lung Cancer

Message from the Guest Editor

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of non-small-cell lung cancer (NSCLC) across advanced disease and, increasingly, perioperative settings. Despite these advances, durable benefit remains limited to a subset of patients, while primary resistance, acquired resistance, and marked biological heterogeneity continue to hinder long-term disease control. This Special Issue aims to provide an interdisciplinary platform for reporting emerging biomarkers associated with sensitivity and resistance to immune checkpoint blockade in NSCLC and for exploring biomarker-guided therapeutic strategies to overcome resistance. We welcome original research articles, reviews, clinical and translational studies, and well-designed exploratory analyses addressing biomarker discovery, validation, mechanistic investigation, and clinical implementation. Topics of interest include, but are not limited to, tissue- and blood-based biomarkers, dynamic monitoring during treatment, mechanisms of resistance, biomarker-integrated patient stratification, and novel combination approaches.

Guest Editor

Dr. Minglei Zhuo

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department I of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing, China

Deadline for manuscript submissions

20 April 2027



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/279614

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)